Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
NCT00086203
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
INDUSTRY
Sponsor class
Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG:
Talabostat mesylate (PT-100) tablets
DRUG:
Rituximab
Sponsor
Point Therapeutics